Evidence map›Paper›PMID 37376419›Full record

ArticleVaccines2023

Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018

Sakshi Bajoria, Ozan S Kumru, Jennifer Doering, Katherine Berman, Greta Van Slyke, Anneka Prigodich, Sergio A Rodriguez-Aponte, Harry Kleanthous, J Christopher Love, Nicholas J Mantis and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Construction ofVaccines · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sakshi BajoriaDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.ORCID 0000-0001-8782-0842
Ozan S KumruDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
Jennifer DoeringDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA.
Katherine BermanDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA.
Greta Van SlykeDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA.
Anneka PrigodichDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA.
Sergio A Rodriguez-AponteDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Harry KleanthousBill & Melinda Gates Foundation, Seattle, WA 98109, USA.
J Christopher LoveThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Nicholas J MantisDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA.ORCID 0000-0002-5083-8640
Sangeeta B JoshiDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
David B VolkinDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.

Funding

High-Throughput Dried Blood Spot (HT-DBS) Technologies in SARS COV-2 Serology and VaccinologyU01CA260508 · NCI · WADSWORTH CENTER · PI MANTIS, NICHOLAS J. · 2020 to 2023
$2.6M
Bill & Melinda Gates Foundation INV-002740 and INV-027417NCI NIH HHS U01 CA260508
6 · The paper itself

Abstract

Aluminum-salt vaccine adjuvants (alum) are commercially available as micron-sized particles with varying chemical composition and crystallinity. There are reports of enhanced adjuvanticity when the alum's particle size is reduced to the nanometer range. Previously, we demonstrated that a recombinant receptor-binding domain (RBD)-based COVID-19 vaccine candidate (RBD-J; RBD-L452K-F490W) formulated with aluminum hydroxide (Alhydrogel

Indexed as

adjuvantCpG 1018formulationimmunogenicitynanoalumnanoparticlestabilityvaccine

Identifiers

PMID37376419
PMCPMC10303432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.